Cargando…

Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is a commonly diagnosed malignancy in southern China and southeast Asia. Previous studies have identified galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a potential biomarker for multiple cancers. However, it is unknown whether GALNS plays a role in NPC development, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin, Ran, Hong, Wang, Zhen, Liu, Peng, Kang, Chenglin, Zeng, Xianhai, Qiu, Shuqi, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501037/
https://www.ncbi.nlm.nih.gov/pubmed/37707658
http://dx.doi.org/10.1007/s12672-023-00782-4
_version_ 1785106040190140416
author Zhang, Jin
Ran, Hong
Wang, Zhen
Liu, Peng
Kang, Chenglin
Zeng, Xianhai
Qiu, Shuqi
Zhang, Peng
author_facet Zhang, Jin
Ran, Hong
Wang, Zhen
Liu, Peng
Kang, Chenglin
Zeng, Xianhai
Qiu, Shuqi
Zhang, Peng
author_sort Zhang, Jin
collection PubMed
description Nasopharyngeal carcinoma (NPC) is a commonly diagnosed malignancy in southern China and southeast Asia. Previous studies have identified galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a potential biomarker for multiple cancers. However, it is unknown whether GALNS plays a role in NPC development, and the underlying mechanisms remain unclear. In this study, we found that GALNS is overexpressed in NPC cell lines and tissues compared to the normal nasopharyngeal counterparts. Knocking down GALNS expression in the NPC cells significantly decreased their proliferation in vitro, and inhibited xenograft growth in a mouse model. Mechanistically, the anti-proliferative effect of GALNS silencing was the result of autophagy induction via the inhibition of PI3K–AKT–mTOR signaling pathway. Taken together, GALNS drives the progression of NPC via PI3K–AKT–mTOR signaling-mediated autophagy, and is therefore a promising therapeutic target. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00782-4.
format Online
Article
Text
id pubmed-10501037
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105010372023-09-15 Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma Zhang, Jin Ran, Hong Wang, Zhen Liu, Peng Kang, Chenglin Zeng, Xianhai Qiu, Shuqi Zhang, Peng Discov Oncol Research Nasopharyngeal carcinoma (NPC) is a commonly diagnosed malignancy in southern China and southeast Asia. Previous studies have identified galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a potential biomarker for multiple cancers. However, it is unknown whether GALNS plays a role in NPC development, and the underlying mechanisms remain unclear. In this study, we found that GALNS is overexpressed in NPC cell lines and tissues compared to the normal nasopharyngeal counterparts. Knocking down GALNS expression in the NPC cells significantly decreased their proliferation in vitro, and inhibited xenograft growth in a mouse model. Mechanistically, the anti-proliferative effect of GALNS silencing was the result of autophagy induction via the inhibition of PI3K–AKT–mTOR signaling pathway. Taken together, GALNS drives the progression of NPC via PI3K–AKT–mTOR signaling-mediated autophagy, and is therefore a promising therapeutic target. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00782-4. Springer US 2023-09-14 /pmc/articles/PMC10501037/ /pubmed/37707658 http://dx.doi.org/10.1007/s12672-023-00782-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Zhang, Jin
Ran, Hong
Wang, Zhen
Liu, Peng
Kang, Chenglin
Zeng, Xianhai
Qiu, Shuqi
Zhang, Peng
Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title_full Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title_fullStr Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title_full_unstemmed Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title_short Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
title_sort identification of galactosamine-(n-acetyl)-6-sulfatase (galns) as a novel therapeutic target in progression of nasopharyngeal carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501037/
https://www.ncbi.nlm.nih.gov/pubmed/37707658
http://dx.doi.org/10.1007/s12672-023-00782-4
work_keys_str_mv AT zhangjin identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT ranhong identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT wangzhen identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT liupeng identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT kangchenglin identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT zengxianhai identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT qiushuqi identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma
AT zhangpeng identificationofgalactosaminenacetyl6sulfatasegalnsasanoveltherapeutictargetinprogressionofnasopharyngealcarcinoma